tcy8722太阳集团

目录产品 » LY6G6D hFc Chimera, Human
Manual
COAs

LY6G6D hFc Chimera, Human

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.
￥3300
Z05619-100

产品简介
Species Human
Protein Construction
LY6G6D (Asn20-Ser104)
Accession # O95868		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 35.87 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
返回

图例
LY6G6D HFc Chimera, Human

Immobilized LY6G6D hFc Chimera, Human, hFc Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-LY6G6D Antibody, hFc Avi Tag with the EC50 of 19.7ng/ml determined by ELISA. »

LY6G6D HFc Chimera, Human

The purity of LY6G6D hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

LY6G6D HFc Chimera, Human

LY6G6D hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

技术背景
Target Background LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.
Synonyms Protein Ly6-D; C6orf23; G6D; MEGT1; NG25
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.